Abstract: The invention relates generally to improving sleep, post-sleep performance, or both and, more particularly, to so improving without inducing post-sleep effects that would impair an individual's ability to operate machinery or a motor vehicle.

Abstract: A composition includes at least one of a modified glucal or galactal molecule. The molecules are useful for the treatment of cancer, particularly in a human patient, more particularly in a human patient exhibiting cell-specific increases in glucose uptake without a corresponding lactate production. The compounds are also useful for treating a human that has hypoxic cells expressing elevated levels of HIT activity, a plurality of cells displaying a lower amplitude of circadian oscillation or an increase in reactive oxygen species in mitochondria of the cells of the human.

Abstract: Dietary supplement compositions for relief of human and animal ailments comprising from 0.1 percent to 50 percent of a Cannabis sativa extract or combinations of a Cannabis sativa extracts and from 10 percent to 99.9 percent of a naturally derived edible oil or combinations of a naturally derived edible oils, where the naturally derived edible oil has a total saturated fat content of less than about 15 percent and a total polyunsaturated fat content greater than 44 percent, said edible oil or combination of said edible oils enhance sublingual and buccal pouch absorption of the Cannabis sativa extract and improve the overall taste of the composition. The composition's taste may be further enhanced with the addition of compatible flavoring agents. To improve the absorption of the Cannabis sativa extract and the compatibility of said flavoring agents, surface active agents may be incorporated. The composition may still further be enhanced by addition of various antioxidants and preservatives.

Abstract: This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heating material to a first temperature and a second temperature.

Abstract: A bioactive formulation including ethanolic concentrates of Andrographolide extract in range of 90% by wt-99% by wt and aqueous 2 hydroxypropyl beta cyclodextrin in the range of 2% by wt-10% by wt. A method for preparation of the bioactive formulation including the following steps: mixing Andrographolide extract and ethanol to prepare ethanolic concentrates of Andrographolide (solvent A), mixing hydroxypropyl beta cyclodextrin and ethanol to obtain an ethanolic concentrate 2 hydroxypropyl beta cyclodextrin (Solvent B), mixing the solvent A and solvent B to obtain a complex concentrate solution, recovering ethanol solvent from the concentrate solution through distillation to obtain a thick paste of the concentrate, drying the paste at a temperature in the range of 55° C.-65° C. and pressure in the range of ?650 to 700 mm Hg to obtain a dried complex concentrate followed by converting into an amorphous powder to obtain a bioactive formulation.

Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Abstract: The present invention provides new GABAA receptor-binding compounds that modify the activation of GABAA, their use in the preparation of a neuroactive pharmaceutical composition, improving sperm motility and labeling of biomolecules.

Abstract: Provided herein are methods of treating IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. Also provided herein are methods of decreasing renal inflammation and/or fibrosis, decreasing the occurrence of hematuria, stabilizing eGFR, decreasing the number of IgA-nephropathy associated disease flares, delaying the onset of ESRD, decreasing proteinuria, and decreasing fatigue in a subject having IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to the subject. In some embodiments, the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV/AIDS, HIV-related nephropathy, prostate cancer, or acute kidney failure.

Abstract: A topical pharmaceutical composition of apremilast used for the treatment of psoriasis and/or psoriatic arthritis is provided. It further relates to processes of preparation of the compositions and the method of use for these compositions.

Abstract: The present invention provides for use of melatonin in the preparation of a medicament for inhibiting and/or killing a bacterium, as well as related compositions, and relates to the technical field of medicines. Methods of prevention and treatment of pathogenic bacteria infection disease states are also provided that leverage the remarkable bacteriostatic or bactericidal effects of melatonin, which damages the metabolic flux of a bacterium by specifically targeting a citrate synthase in a gram-negative bacterium. In an in vivo infection model of Pasteurella multocida, melatonin effectively reduces bacterial colonization in the lung and improves survival rate of mice.

Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.

Abstract: Methods of safely administrating a gut-selective JAK3 inhibitor by oral administration are described. Also described are methods for providing clinically proven safe treatment of gastrointestinal inflammatory diseases, such as celiac disease, by oral administration of a gut-selective JAK3 inhibitor.

Abstract: Materials and methods for detecting and treating Coccidioidomycosis (Valley Fever) are provided herein. For example, materials and methods for enriching and detecting biomarker antigens (e.g., polypeptides and/or glycans) from Coccidioides immitis and Coccidioides posadasii, the fungi that cause Valley Fever, are described herein, as are methods for treating an individual for Valley Fever based on the results of the described detection methods.

Abstract: The present disclosure relates a method of treating chondrosarcoma or suppressing metastasis or recurrence thereof by regulating HIF-2?. The present method can be effectively used for treating chondrosarcoma or suppressing metastasis or recurrence thereof by inhibiting HIF-2? during the development and metastasis of chondrosarcoma, particularly dedifferentiated chondrosarcoma.

Abstract: Compositions and methods for treating hair loss in a patient by administering a composition having an active agent in a mixed solvent containing an aqueous phase and an oil phase are described herein.

Abstract: Provided herein are combination therapies comprising GDC-9545 and a CDK4/6 inhibitor for treating locally advanced breast cancer or metastatic breast cancer.

Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Abstract: A bowel cleansing composition includes as a first cleansing ingredient, a specific sugar alcohol such as xylitol, sorbitol, etc., as a second cleansing ingredient glycerol, erythritol, threitol, arabitol, ribitol, mannitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, and polyglycitol, as a second cleansing ingredient ascorbic acid or a mixture of ascorbic acid and a salt of ascorbic acid, as a third cleansing ingredient picosulfate, and an aqueous solvent, wherein the concentration of the first cleansing ingredient is 10 g/L to 500 g/L based on the total composition, the concentration of the second cleansing ingredient is 15 g/L to 500 g/L based on the total composition, the concentration of the third cleansing ingredient is 1 mg/L to 100 mg/L based on the total composition, and the volume of the aqueous solvent is 0.1 L to 1.0 L.

Abstract: The present application discloses a compound which is which activates Wnt/?-catenin signaling and thus treats or prevents diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

Abstract: Provided herein is a method for treating an oral cancer in a subject. According to embodiments of the present disclosure, the method comprises respectively obtaining a first and a second biological samples from a lesion site and a non-lesion site of the subject; respectively measuring the expression levels of CHEK1, PIK3CA, or PIK3CD in both biological samples by qRT-PCR thereby obtaining a first and a second expression level; determining the ratio of the first to the second expression level; and administering to the subject an effective amount of a checkpoint kinase 1 inhibitor when the ratio for CHEK1 is at least 1.7 or a phosphatidylinositol 3-kinase inhibitor when the ratio for PIK3CA is at least 2.4, or when the ratio for PIK3CD is at least 3.1.

Abstract: The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.

Abstract: The development of a new, targeted drug delivery paradigm coupled to improved PI3K inhibitors (e.g., PI3K? inhibitors) represents a significant advance in cancer therapy. Provided herein are compounds, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds provided herein are PI3K (e.g., PI3K?) inhibitors and are therefore useful for the treatment and/or prevention of various diseases (e.g., proliferative diseases such as cancer). Also provided herein are nanoparticles and nanogels (e.g., P-selectin targeting nanoparticles) comprising PI3K inhibitors, such a compound described herein. In certain embodiments, a nanoparticle or nanogel described herein encapsulates a compound described herein for targeting delivery to cancer cells or tumors.

Abstract: The invention relates to new pyridinyl sulfonamide derivatives of the formula wherein R1, A and n are as defined herein, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: Provided are methods for treating, ameliorating, reversing and/or preventing a Helicobacter pylori (H. pylori) infection in an individual in need thereof, comprising: administering to the individual in need thereof a therapeutic combination comprising: (a) a composition comprising or consisting of: vonoprazan or a vonoprazan fumarate, or a 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine monofumarate, or a 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methyl-methanamine fumarate), optionally TAKECAB™; and (b) an antimicrobial or antibiotic drug or composition.

Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R1c, E, G, and Q are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to inhibition of menin.

Abstract: A method of treating ALS in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount at least two metabolites.

Abstract: The present disclosure provides a method of treating a condition associated with aging, including a disease or condition selected from anemia, including unexplained anemia of the elderly, spontaneous anemia of aging, and anemia of inflammation in the elderly, sarcopenia, frailty, tissue injury, muscle injury, and ischemic damage, the method comprising administering to an elderly subject a therapeutically effective amount of a hypoxia-inducible factor prolyl hydroxylase inhibitor.

Abstract: The invention is directed to (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H- dibenzo[de,g]quinoline-10,11-diol for the treatment of diseases mediated by protein misfolding of Cu/Zn Superoxide Dismutase (SOD1) or mediated by astrocyte toxicity affecting motor neuron survival.

Abstract: The present invention relates to compounds that can be used to induce immunogenic cell death (ICD). In some instances, two or more compounds are combined to induce ICD. The invention also relates to the combination of ICD-inducing compounds with an agent stimulating the immune system, such as an immune checkpoint inhibitor, in particular, to 5 treat cancer or inhibit tumor growth.

Abstract: This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.

Abstract: The present disclosure relates generally to methods of inhibiting a tripartite VAP-A, ORP3 and Rab7 (VOR) protein complex in multicellular organisms, to methods of identifying agents which inhibit such complex and to the medical use of those agents. Inhibition of the VOR complex causes interference with at least one mechanism of intercellular communication, wherein the intercellular communication is mediated by receptor-ligand interaction and/or EVs, and viral infection involving the transport of endocytosed biomaterials to the nucleus of recipient cells.

Abstract: The invention provides compositions and methods for treating a subject having a rheumatic condition.

Abstract: Compositions for delivering a drug to a subject having: a plurality of self-assembled supramolecular nanoparticles (SMNPs), each of the plurality of self-assembled supramolecular nanoparticles (SMNPs) having: a plurality of binding components, each having a plurality of binding regions; a plurality of cores that are suitable to at least provide some mechanical structure to the plurality of self-assembled supramolecular nanoparticles (SMNPs), the plurality of cores comprising at least one core binding element adapted to bind to the binding regions to form a first inclusion complex; a plurality of terminating components, each having a single terminating binding element that binds to remaining binding regions of one of said plurality of binding components by forming a second inclusion complex; the drug; and a reporter agent, and methods of use thereof.

Abstract: Provided herein are methods and therapeutic combinations useful in the treatment of venetoclax-resistant Acute Myeloid Leukemia and of venetoclax-sensitive Acute Myeloid Leukemia.

Abstract: Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

Abstract: The present application relates to treating and/or preventing prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, X1, X2, X3, X4, and n are defined herein.

Abstract: Compositions and methods for treating hair loss in a patient by intradermal injection using liquid composition containing minoxidil and a secondary active agent in a pharmaceutically acceptable excipient are described herein.

Abstract: The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.

Abstract: Provided herein are methods of treating cancer with a TPH1 inhibitor. In certain embodiments, methods are provided which display remarkable efficacy and bioavailability for the treatment of certain tumors, for example, a neuroendocrine tumor in a human patient. In certain embodiments, the methods comprising treating the patient with telotristat, a telotristat prodrug, or a pharmaceutically acceptable salt thereof, which can be administered either alone or in combination with other anticancer or antidiarrheal agents.

Abstract: Methods of treating irregular sleep-wake rhythm disorder in subjects and compositions for use in the same are disclosed.

Abstract: Provided herein are modulators of beta-adrenergic receptors.

Abstract: This document discloses a novel class of quinazoline EGFR inhibitors. Also disclosed are pharmaceutical compositions thereof and method for treating cancers. Disclosed herein is a novel class of quinazoline compounds which selectively and effectively inhibit the growth of cancer cells induced by the overexpression of an epidermal growth factor receptor (EGFR).

Abstract: The present disclosure provides compounds and methods of use thereof for treating inflammatory diseases or disorders.

Abstract: Provided herein are combinations of compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.

Abstract: The present invention includes name compounds of general formula (I): (I) in which R1, R2, R3 and R4 are as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their use for the treatment of hyperproliferative diseases.

Abstract: The present invention includes a method of treating a cancer or neurodegenerative disease in a subject in need thereof, the method comprising administering directly into the malignant glioma or intravenously to the subject a therapeutically effective amount of a compound of formula:

Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

Abstract: The invention relates to a pharmaceutical composition comprising 5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl} phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-1H-pyrrole-3-carboxamide, referred to herein as ‘Compound A’, or a pharmaceutically acceptable salt thereof, and a cyclodextrin. More specifically, the invention relates to a solid pharmaceutical composition comprising Compound A and a cyclodextrin, and a pharmaceutical composition for parenteral administration prepared by dissolving this solid pharmaceutical composition. Furthermore, the invention relates to the use of such compositions for the treatment of cancer.

Abstract: Pharmaceutical compositions comprising filgotinib maleate Form I and uses thereof are described herein.

Abstract: The present invention relates to an aqueous ophthalmic solution for treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma, the solution comprising at least 0.5 w/v % brinzolamide dissolved in the solution; hydroxy-propyl-?-cyclodextrin; polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer; and water and/or the process for preparation thereof.